Page 16 - CUA 2020_BPH

Moderated Posters 7: BPH

MP-7.3. Table 1A. Patient demographics MP-7.4
Demographic Mean Count Aquablation for benign prostatic hyperplasia in large prostates
Age 68.4 34 (80–150cc): Two-year results 2 3
1
Kevin C. Zorn , Naeem Bhojani , Dean S. Elterman , S. Larry Goldenberg ,
1
Duration of BPH, years Alan I. So , Ryan F. Paterson , Mihir Desai , Steven Kaplan , Roehrborn
4
5
3
3
<5 10 Roehrborn 5
1 Urology, Centre hospitalier de l’Université de Montréal, Montreal, QC,
5–7 9 Canada; Urology, University of Toronto, Toronto, ON, Canada; Urology,
3
2
8–10 8 University of British Columbia, Vancouver, BC, Canada; Urology, UTSW,
4
5
>10 7 Dallas, TX, United States; Urology, USC, Los Angeles, CA, United States
Median lobe Support: WATER2 Study Group (ClinicalTrials.gov number, NCT03123250)
Introduction: We aimed to report two-year safety and effectiveness out-
Yes 26 comes of the Aquablation procedure for the treatment of men with symp-
No 8 tomatic benign prostatic hyperplasia (BPH) and large-volume prostates.
Previous BPH surgery Methods: A total of 101 men with moderate-to-severe BPH symp-
toms and prostate volumes of 80–150 cc underwent a robotic-assisted
TURP 2 Aquablation procedure in a prospective, multicenter, international clini-
PAE 1 cal trial. Functional and safety outcomes were assessed at two years
Current BPH medication postoperatively.
Results: Mean prostate volume was 107 cc (range 80–150). Mean opera-
Alpha-blocker 26 tive time was 37 minutes and mean Aquablation resection time was eight
5ARI 7 minutes. The average length of hospital stay following the procedure was
Cialis/Viagra 4 1.6 days. International Prostate Symptom Score (IPSS) scores improved
from 23.2 at baseline to 5.1 at two years (change score of 18.1 points).
None 7 At baseline, maximum flow rate (Qmax) was 8.7 cc/sec and improving
Medical history to 16.6 cc/sec at 24 months. Improvements in both IPSS and Qmax were
Kidney/bladder stone 3 immediate and sustained throughout followup. The average annual retreat-
ment occurrence was 0%.
Hypertension 9 Conclusions: The Aquablation procedure is demonstrated to be safe and
Diabetes 4 effective in treating men with large prostates (80–150 cc) after two year of
Dyslipidemia 7 followup, with an acceptable complication rate and without a significant
increase in procedure or resection time compared to smaller sized glands.
History of urinary retention 6 Two-year results held consistent with one-year outcomes.
was 98.9 ml (range 80–160 ml) and 76% had a median lobe. Six of MP-7.5
them had a history of urinary retention. On average, patients received Transfusion rates after 800 Aquablation procedures using various
13 Rezūm injections. Visibility and bleeding during the procedure were hemostasis methods
assessed using a five-point scale, and were rated as 1.7 and 1.8, respec- 1 2 3 4
tively. Catheter was placed for 5–10 days and was extended to a month Dean S. Elterman , Thorsten Bach , Enrique Rijo , Vincent Misrai , Paul
5
6
7
8
6
in patients with pre-existing retention. Two patients needed catheter Anderson , Kevin C. Zorn , Naeem Bhojani , Albert El Hajj , Bilal Chughtai ,
9
replacement due to postoperative retention. The preliminary one-month, Mihir Desai 2
1
three-month, and six-month followup results were analyzed (Table 1). Urology, University Health Network, Toronto, ON, Canada; Urology,
3
At one month and three months, Qmax had improved by 24.9% and Asklepios Hospital Harburg, Hamburg, Germany; Urology, Hospital Quirón
4
5
53.4%, while PVR by 56.6% and 68.7%, respectively. Improvement on Salud, Barcelona, Spain; Urology, Clinique Pasteur, Toulouse, France; Urology,
6
prostate symptoms was also reflected by the IPSS, IPSS QoL, and BPHII Royal Melbourne Hospital, Melbourne, Australia; Urology, Centre hospitalier
7
scores by 32.4%, 38.2%, and 14.4%, respectively at one month, and more de l’Université de Montréal, Montreal, QC, Canada; Urology, American
8
prominently at three months (55.2%, 60.7%, and 61.8%, respectively). University of Beirut Medical Center, Beirut, Lebanon; Urology, Weill Cornell
9
Minimal impact on sexuality was observed. Medical College, New York, NY, United States; Urology, University of
Conclusions: Herein we demonstrate that Rezūm therapy is a viable treat- Southern California, Los Angeles, CA, United States
ment modality in prostate glands ≥80 ml. Introduction: Many studies have evaluated the bleeding complication
profile postoperatively for transurethral resection of the prostate (TURP)
MP-7.3. Table 1B. Baseline data
Mean SD Median Count Min Max
Qmax (ml/sec) 8.2 4.4 8.0 30 2.0 19.0
PVR (ml) 194.0 181.5 146.0 27 2.0 820.0
Prostate volume (ml) 98.9 18.7 95.0 34 80.0 160.0
PSA (ug/L) 8.0 16.2 4.5 34 0.8 98.0
IPSS 20.9 7.2 22.0 33 6 35
IPSS QoL 4.4 1.2 5.0 33 2 6
BPHII 7.0 2.9 7 30 0 12
IIEF 48.8 19.7 57 27 12 71
MSHQ function 9.4 3.5 9 24 4 15
MSHQ bother 1.7 1.8 1.5 24 0 5
CUAJ • June 2020 • Volume 14, Issue 6(Suppl2) S117